Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > A case for voting out Gary Littlejohn

<< Previous

Bullboard Posts

Next >>

Comment by retiredRIAon May 04, 2021 8:06am

145 Views

Post# 33121855

RE:RE:RE:RE:RE:A case for voting out Gary Littlejohn

It appears from his BIO that Gary Littlejohn has minimal contact with US firms and his pultry number of THTX shares shows he doesn't have EITHER the passion or contacts to attract US buyers. We know there are not enough of us to vote Gary off but we will "send a message" to both Gary and management that we are expecting more from a board member put in this slot.

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo